Why ARNT Prostate Tumors Responding to Enzalutamide?

Meng Zhang Thaidy Moreno-Rodriguez David A Quigley

Published in: Cancer discovery (2022)

Prostate tumors can develop resistance to androgen receptor (AR)-targeted therapies through treatment-induced changes in transcription factor activity that promote transcriptional and morphologic features of a neuroendocrine lineage. This study identifies an unexpected role for the circadian protein ARNTL in resistance to enzalutamide, a second-generation AR-targeted therapy. See related article by Linder et al., p. 2074 (4).

Keyphrases

prostate cancer
transcription factor
benign prostatic hyperplasia
gene expression
genome wide
single cell
dna methylation
amino acid